Targeted therapy of multiple myeloma by IL21-NKG2D CAR-T cells

Area of Science:

• Immunotherapy
• Oncology
• Cellular Engineering

Background:

• Chimeric antigen receptor (CAR)-T cell therapy shows promise in treating various cancers.
• NKG2D CAR-T cells have demonstrated preclinical efficacy, but their potential in multiple myeloma (MM) requires further investigation.
• The role of IL-21 co-expression in enhancing CAR-T cell activity against MM is not well understood.

Purpose of the Study:

• To engineer and evaluate IL-21 co-expressing NKG2D CAR-T cells (IL21-NKG2D CAR-T cells) for enhanced antitumor activity against multiple myeloma (MM).
• To assess the in vitro and in vivo efficacy of IL21-NKG2D CAR-T cells in eliminating MM cells.
• To investigate the synergistic effect of dexamethasone with IL21-NKG2D CAR-T cells in MM treatment.

Main Methods:

• Lentiviral vectors were produced to construct IL21-NKG2D CAR-T cells and NKG2D CAR-T cells.
• CAR expression was confirmed using flow cytometry.
• In vitro cytotoxicity assays (cytotoxicity assay and ELISA) and in vivo xenograft models were used to evaluate anti-MM activity.

Main Results:

• NKG2D CAR-T cells exhibited significant cytotoxicity against MM cells in vitro.
• Co-expression of IL-21 markedly enhanced the cytotoxic activity of NKG2D CAR-T cells against MM cells.
• IL21-NKG2D CAR-T cells demonstrated substantial anti-myeloma activity in vivo, which was further augmented by dexamethasone.

Conclusions:

• IL21-NKG2D CAR-T cells possess potent in vitro and in vivo cytotoxicity against multiple myeloma.
• A therapeutic strategy combining IL21-NKG2D CAR-T cells with low-dose dexamethasone shows potential for future MM targeted therapy.
• This study establishes a foundation for further research into advanced CAR-T cell therapies for MM.